Lucid-MS
| Clinical data | |
|---|---|
| Other names | Lucid-21-302 |
| Routes of administration | Oral[1][2] |
| Drug class | Protein arginine deiminase 2 (PAD2) inhibitor |
| ATC code |
|
| Pharmacokinetic data | |
| Elimination half-life | 1.5–2.5 hours[2] |
Lucid-MS, also known as Lucid-21-302, is a protein arginine deiminase 2 (PAD2) inhibitor which is under development for the treatment of multiple sclerosis.[1][3][4][2] It is taken orally.[1][2]
The drug is described as a non-immunomodulatory neuroprotective agent against demyelination and is said to be a potential first-in-class medication.[1][4][2] The pharmacokinetics of Lucid-MS have been described.[4][2]
It was originated by University Health Network and has been developed by FSD Pharma, Lucid Psycheceuticals, and Quantum Biopharma.[1][3][4] As of February 2026, Lucid-MS is in phase 1 clinical trials, with at least one phase 1 trial having been completed and published.[1][3][4][2] A phase 2 trial is being planned.[4] The chemical structure of Lucid-MS does not yet appear to have been disclosed.[1]
See also
References
- ^ a b c d e f g "Lucid MS". AdisInsight. Springer Nature Switzerland AG. 16 March 2025. Retrieved 27 March 2026.
- ^ a b c d e f g Chruscinski A, Joshi A, Stys P, Antel J, Kotra L (February 2026). P131 / P131 - Results of a Phase 1 Multiple Ascending Dose Trial of Lucid-21-302 (Lucid-MS) in Healthy Volunteers: A Novel Myelin Protective Small Molecule to Prevent Disease Progression in Multiple Sclerosis. 2026 ACTRIMS Forum. San Diego, CA. Abstract P131.
- ^ a b c "Delving into the Latest Updates on Lucid 21 302 with Synapse". Synapse. 13 December 2025. Retrieved 27 March 2026.
- ^ a b c d e f Meglio M (27 March 2026). "Myelin Protective Small Molecule Lucid-MS Shows Promising Early-Stage Data in Healthy Volunteers". NeurologyLive. Retrieved 27 March 2026.